Heat Shock Protein 90 Interactome-Mediated Proteolysis Targeting Chimera (HIM-PROTAC) Degrading Glutathione Peroxidase 4 to Trigger Ferroptosis
Journal of Medicinal Chemistry · 26.09.2024 · 67 (18) · 16712-16736
DOI: 10.1021/acs.jmedchem.4c01518 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 04.09.2024. Verfasst von Jinyun Dong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China. Hauptthemen laut MEDLINE: Ferroptosis, HSP90 Heat-Shock Proteins, Phospholipid Hydroperoxide Glutathione Peroxidase, Proteolysis. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Science and Technology Department of Zhejiang Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Targeted protein degradation (TPD) is an emerging therapeutic paradigm aimed at eliminating the disease-causing protein with aberrant expression. Herein, we report a new approach to inducing intracellular glutathione peroxidase 4 (GPX4) protein degradation to trigger ferroptosis by bridging the target protein to heat shock protein 90 (HSP90), termed HSP90 interactome-mediated proteolysis targeting chimera (HIM-PROTAC). Different series of HIM-PROTACs were synthesized and evaluated, and two of them, GDCNF-2/GDCNF-11 potently induced ferroptosis via HSP90-mediated ubiquitin-proteasomal degradation of GPX4 in HT-1080 cells with DC50 values of 0.18 and 0.08 μM, respectively. In particular, GDCNF-11 showed 15-fold more ferroptosis selectivity over GPX4 inhibitor ML162. Moreover, these two degraders effectively suppress tumor growth in the mice model with relatively low toxicity as compared to the combination therapy of GPX4 and HSP90 inhibitors. In general, this study demonstrated the feasibility of degrading GPX4 via HSP90 interactome, and thus provided a significant complement to existing TPD strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
- Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province, Hangzhou 310022, China.
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310032, China.
ORCID-Profile: Juan Li, Jiang-Jiang Qin
Förderung
- National Key Research and Development Program of China
- Science and Technology Department of Zhejiang Province
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province
Zitieren
APA
Dong, J., Ma, F., Cai, M., Cao, F., Li, H., Liang, H., Li, Y., Ding, G., Li, J., Cheng, X., & Qin, J. J. (2024). Heat Shock Protein 90 Interactome-Mediated Proteolysis Targeting Chimera (HIM-PROTAC) Degrading Glutathione Peroxidase 4 to Trigger Ferroptosis. Journal of Medicinal Chemistry, 67(18), 16712-16736. https://doi.org/10.1021/acs.jmedchem.4c01518
Vancouver
Dong J, Ma F, Cai M, Cao F, Li H, Liang H, et al. Heat Shock Protein 90 Interactome-Mediated Proteolysis Targeting Chimera (HIM-PROTAC) Degrading Glutathione Peroxidase 4 to Trigger Ferroptosis. Journal of Medicinal Chemistry. 2024;67(18):16712-16736. doi:10.1021/acs.jmedchem.4c01518
BibTeX
@article{Dong2024,
author = {Dong, Jinyun and Ma, Furong and Cai, Maohua and Cao, Fei and Li, Haobin and Liang, Hui and Li, Yulong and Ding, Guangyu and Li, Juan and Cheng, Xiangdong and Qin, Jiang-Jiang},
title = {Heat Shock Protein 90 Interactome-Mediated Proteolysis Targeting Chimera (HIM-PROTAC) Degrading Glutathione Peroxidase 4 to Trigger Ferroptosis},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {18},
pages = {16712--16736},
doi = {10.1021/acs.jmedchem.4c01518}
}
EUVIMED